July 28, 2021
1 min read

Pfizer recommends 3rd Covid shot for Delta variant

Pfizer anticipates applying for emergency use authorization for a third dose of its vaccine as soon as next month…reports Asian Lite News

 American biopharmaceutical company Pfizer has said a third dose of its Covid-19 vaccine can “strongly” boost protection against the Delta variant.

Antibody levels against the Delta variant in people aged 18 to 55 who receive a third dose of the Pfizer/BioNTech vaccine are greater than five-fold than following a second dose, according to data posted at the company’s teleconference, Xinhua reported.

Among people aged 65 to 85, the Pfizer data suggest that antibody levels against the Delta variant after receiving a third dose are greater than 11-fold than following a second dose.

Pfizer anticipates applying for emergency use authorization for a third dose of its vaccine as soon as next month, Mikael Dolsten, who leads worldwide research, development and medical for Pfizer, was quoted by CNN as saying at the teleconference.

ALSO READ: Nepal confirms new mutant of Delta variant of Covid-19

Previous Story

Taliban Targets Pakistan’s Dirty Bomb Assets

Next Story

Olympic city Tokyo’s daily Covid cases cross 3,000 for 1st time

Latest from -Top News

Trump needs to remember the 2026 midterms 

Were the Executive Order restrictions on birth-right citizenship not removed before the 2026 midterm polls, not just Indian-Americans but Hispanic Americans as well would shift from Republicans to the Democrats, writes Prof.

DeepSeek draws global flak over Uyghur censorship 

China’s AI model, DeepSeek, is under scrutiny for allegedly promoting state propaganda, censoring sensitive topics, and harvesting personal data, raising global privacy and human rights concerns.  Human rights activists and international experts
Go toTop

Don't Miss

Global Covid-19 Cases Top 197.2 Mn

The Covid-19 outbreak first detected in the Chinese city of

Britain’s vaccine passport plans to be scrapped

Move comes amidst mounting concern over the prospect of vaccine